Target intelligence / Profile preview

Glycerol-3-phosphate dehydrogenase 2 (GPD2)

Target
GPD2
Molecular classification
Enzyme, Flavoprotein oxidoreductase, Mitochondrial protein
01

Overview

Glycerol-3-phosphate dehydrogenase 2 (GPD2) is a mitochondrial enzyme that catalyzes the oxidation of glycerol-3-phosphate to dihydroxyacetone phosphate, transferring electrons from FAD to ubiquinone in the electron transport chain. This reaction forms a critical part of the glycerol phosphate shuttle, connecting glycolysis and oxidative phosphorylation, regulating NAD+/NADH balance, and contributing to lipid biosynthesis. GPD2 is structurally conserved and shares homology with bacterial GlpD, which has been extensively characterized. GPD2 plays essential roles in cellular metabolism, is regulated under various stress conditions, and alterations in its activity are associated with cancer, obesity, and diabetes. It is a candidate metabolic target but not the subject of approved direct drugs at present.

Other names
mitchondrial glycerol-3-phosphate dehydrogenaseGPD2GlpD (ortholog in bacteria)alphaGPDHGPDH (less specific; encompasses the family)
02

Mechanism of action

Inhibitors would block electron transfer from glycerol-3-phosphate, impairing NADH/FADH2 reoxidation and mitochondrial function. Targeting GPD2 could disrupt the glycerol phosphate shuttle, affecting glycolysis and lipid biosynthesis.

03

Biological functions

Oxidation of glycerol-3-phosphate to dihydroxyacetone phosphateElectron transfer to the respiratory chain (via FAD and ubiquinone)Regulation of NAD+/NADH ratioGlycerolipid metabolismLinks glycolysis and oxidative phosphorylation
04

Disease associations

Cancer (altered expression in tumors impacting metabolism)Obesity (perturbations in glycerol metabolism)Diabetes and insulin resistance (influences insulin signaling)Cardiovascular disease (implicated via mitochondrial energy metabolism)Other metabolic disorders
05

Safety considerations

Mitochondrial toxicity: as a central metabolic enzyme, inhibition may cause broad metabolic dysfunctionEnergy depletion: blockade may impair ATP production, with implications for tissues highly dependent on mitochondrial metabolism
06

Interacting drugs

No direct drugs currently approved targeting GPD2; experimental inhibitors and molecules such as ubiquinone analogs have been studied in structural and functional assays

1 more in the full profile.

07

Biomarkers

Altered GPD2 expression levels have been suggested as biomarkers in cancer and metabolic disease researchMetabolite levels (glycerol-3-phosphate, dihydroxyacetone phosphate) may indirectly indicate target activity

Beyond the preview

Go deeper on Glycerol-3-phosphate dehydrogenase 2 (GPD2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glycerol-3-phosphate dehydrogenase 2 (GPD2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call